The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Survival outcomes of patients with multiple myeloma in France
Xavier Leleu, MD, PhD, Poitiers University Hospital, Poitiers, France, comments on the results of a real-world longitudinal retrospective study evaluating the survival outcomes of patients with multiple myeloma in France from diagnosis and by line of therapy. Dr Leleu discusses the aims of this study, explaining that previous studies have estimated that 20% of patients die in between each line of therapy, and highlighting issues with the way clinical trials are currently conducted. Overall, the study confirmed that patients have a gradual decrease in overall survival (OS) from diagnosis and with subsequent lines of therapy. In addition, the study highlighted the importance of the first three lines of therapy, as well as the lack of access to therapies beyond third-line. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Janssen, Takeda, BMS, GSK
